GRFS (Grifols) Total Equity: $9,072 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $9.81
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Total Equity?

Grifols GRFS +2.08% 84 Total Equity is $9,072 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $9.81 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Grifols's total equity for the quarter that ended in Mar. 2026 was $9,072 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Grifols Total Equity Historical Data

* Premium members only.

The historical data trend for Grifols's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Total Equity Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,267.91 8,449.29 8,193.78 9,011.52 8,902.81

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 8,763.73 8,859.11 8,902.81 9,071.68
GRFS
84GF Score
Grifols SA GRFS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Grifols's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=23081.967-14179.157
=8,903

Grifols's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=23211.561-14139.884
=9,072

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $9,072 Mil mean?
Grifols (GRFS) has a Total Equity of $9,072 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Grifols and its competitors.
Is Grifols' Total Equity too high?
Grifols' current Total Equity is $9,072 Mil. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Total Equity compare to LLY and JNJ?
Grifols' Total Equity of $9,072 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Grifols and its competitors. Grifols's current Total Equity is $9,072 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $7.36 — trading 25% below its estimated fair value. The current Total Equity is $9,072 Mil. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Grifols (GRFS), the current Total Equity is $9,072 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 25% below its estimated GF Value™ of $9.81. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Total Equity: $9,072 Mil
  • GF Value™: $9.81 vs. price of $7.36 (25% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$9.81
GF Value